Loading patent…
AssigneeBioXcel Therapeutics, Inc.
InventorsKrishnan NANDABALAN, Frank YOCCA, Sameer SHARMA
Estimating the term…
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
A method of treating agitation in an agitated subject comprising administering to the oral mucosa of said subject an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof without also causing significant sedation within about 60 minutes after the administration, wherein the subject has dementia.
The method according to claim 22, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is dexmedetomidine hydrochloride.
A method of treating agitation in an agitated dementia subject comprising administering dexmedetomidine to the subject;
Dependencies are inferred from the claim text.